PTH and hyperphosphatemia: With the expansion of use, it is estimated that half of the patients using oral calcitriol would be indicated for paricalcitol because they persist with PTH levels above 300 pg/mL, in the absence of hypercalcemia and hyperphosphatemia, increasing to 20% of patients on dialysis the use of paricalcitol.